Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD79b-19 CAR T Cells in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06026319Phase 1Recruiting
- Start
- Oct 2023
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD79b CAR-T cells in non-Hodgkin lymphoma (NHL). Primary endpoints: Incidence of adverse events and Incidence of Dose Limiting Toxicity. Started Oct 2023; status: recruiting.
02
Drugs
CD79b CAR-T cells
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06026319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026319.